Fiera Capital Corp Takes Position in Outset Medical, Inc. (NASDAQ:OM)

Fiera Capital Corp bought a new position in shares of Outset Medical, Inc. (NASDAQ:OMGet Rating) in the 4th quarter, Holdings Channel reports. The fund bought 573,082 shares of the company’s stock, valued at approximately $26,413,000.

Several other hedge funds also recently made changes to their positions in OM. Allspring Global Investments Holdings LLC acquired a new stake in Outset Medical in the 4th quarter worth about $92,901,000. BlackRock Inc. raised its stake in Outset Medical by 26.1% in the 3rd quarter. BlackRock Inc. now owns 4,830,578 shares of the company’s stock worth $238,821,000 after purchasing an additional 999,308 shares in the last quarter. Alliancebernstein L.P. raised its stake in Outset Medical by 55.6% in the 3rd quarter. Alliancebernstein L.P. now owns 2,276,036 shares of the company’s stock worth $112,527,000 after purchasing an additional 813,138 shares in the last quarter. FIL Ltd raised its stake in Outset Medical by 290.5% in the 3rd quarter. FIL Ltd now owns 834,751 shares of the company’s stock worth $41,270,000 after purchasing an additional 621,005 shares in the last quarter. Finally, Wasatch Advisors Inc. acquired a new stake in Outset Medical in the 3rd quarter worth about $20,592,000.

Shares of Outset Medical stock traded down $1.12 during midday trading on Friday, hitting $34.88. 286,209 shares of the company traded hands, compared to its average volume of 233,583. Outset Medical, Inc. has a 12 month low of $33.29 and a 12 month high of $60.33. The company has a current ratio of 7.93, a quick ratio of 7.17 and a debt-to-equity ratio of 0.08. The firm’s fifty day moving average price is $42.68 and its 200-day moving average price is $44.24.

Outset Medical (NASDAQ:OMGet Rating) last posted its earnings results on Wednesday, February 16th. The company reported ($0.87) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.04). Outset Medical had a negative return on equity of 34.68% and a negative net margin of 128.59%. The business had revenue of $28.15 million for the quarter, compared to the consensus estimate of $26.55 million. Equities research analysts forecast that Outset Medical, Inc. will post -3.1 earnings per share for the current fiscal year.

In other news, General Counsel John L. Brottem sold 10,002 shares of the company’s stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $35.92, for a total value of $359,271.84. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, General Counsel John L. Brottem sold 2,415 shares of the company’s stock in a transaction on Monday, April 18th. The shares were sold at an average price of $43.25, for a total transaction of $104,448.75. Following the completion of the sale, the general counsel now directly owns 34,014 shares in the company, valued at $1,471,105.50. The disclosure for this sale can be found here. Insiders have sold a total of 137,684 shares of company stock worth $6,077,094 over the last three months. Insiders own 5.60% of the company’s stock.

Several equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Outset Medical from a “sell” rating to a “hold” rating in a research report on Saturday, April 16th. Morgan Stanley upgraded shares of Outset Medical from an “equal weight” rating to an “overweight” rating and dropped their target price for the company from $55.00 to $50.00 in a research report on Thursday, February 17th. Bank of America assumed coverage on shares of Outset Medical in a research report on Wednesday, March 2nd. They issued a “buy” rating for the company. Finally, Cowen dropped their target price on shares of Outset Medical from $70.00 to $60.00 in a research report on Thursday, February 17th.

Outset Medical Company Profile (Get Rating)

Outset Medical, Inc, a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.

Read More

Want to see what other hedge funds are holding OM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Outset Medical, Inc. (NASDAQ:OMGet Rating).

Institutional Ownership by Quarter for Outset Medical (NASDAQ:OM)

Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.